BioCentury | Nov 24, 2020
Product Development
Nov. 23 Quick Takes: NIH panel says bamlanivimab should not be considered COVID-19 SOC; plus Eiger, Shionogi-Roche, Kiniksa, Schrödinger, Halozyme-Horizon and Immunicum-DCPrime
...companies’ lead cell-based cancer vaccines are in Phase II testing. DCPrime investors, including majority shareholder Van Herk Investments...